Another KRAS variant trapped

Kenneth Westover

doi:10.1038/s41589-024-01556-x

Another KRAS variant trapped

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

Inhibitors of KRAS G12C have shown that directly targeting RAS is possible, but G12C is only one of many RAS driver mutations. Covalent targeting of another major variant, G12D, raises hope for treating other groups of patients with KRAS-mutant tumors.

Original language	English (US)
Pages (from-to)	1096-1097
Number of pages	2
Journal	Nature chemical biology
Volume	20
Issue number	9
DOIs	https://doi.org/10.1038/s41589-024-01556-x
State	Published - Sep 2024
Externally published	Yes

ASJC Scopus subject areas

Molecular Biology
Cell Biology

Access to Document

10.1038/s41589-024-01556-x

Cite this

@article{77c42c9d1d4643759c6120b9ce895130,

title = "Another KRAS variant trapped",

abstract = "Inhibitors of KRAS G12C have shown that directly targeting RAS is possible, but G12C is only one of many RAS driver mutations. Covalent targeting of another major variant, G12D, raises hope for treating other groups of patients with KRAS-mutant tumors.",

author = "Kenneth Westover",

note = "Publisher Copyright: {\textcopyright} Springer Nature America, Inc. 2024.",

year = "2024",

month = sep,

doi = "10.1038/s41589-024-01556-x",

language = "English (US)",

volume = "20",

pages = "1096--1097",

journal = "Nature chemical biology",

issn = "1552-4450",

publisher = "Nature Publishing Group",

number = "9",

}

TY - JOUR

T1 - Another KRAS variant trapped

AU - Westover, Kenneth

N1 - Publisher Copyright: © Springer Nature America, Inc. 2024.

PY - 2024/9

Y1 - 2024/9

N2 - Inhibitors of KRAS G12C have shown that directly targeting RAS is possible, but G12C is only one of many RAS driver mutations. Covalent targeting of another major variant, G12D, raises hope for treating other groups of patients with KRAS-mutant tumors.

AB - Inhibitors of KRAS G12C have shown that directly targeting RAS is possible, but G12C is only one of many RAS driver mutations. Covalent targeting of another major variant, G12D, raises hope for treating other groups of patients with KRAS-mutant tumors.

UR - http://www.scopus.com/inward/record.url?scp=85186633943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85186633943&partnerID=8YFLogxK

U2 - 10.1038/s41589-024-01556-x

DO - 10.1038/s41589-024-01556-x

M3 - Comment/debate

C2 - 38443471

AN - SCOPUS:85186633943

SN - 1552-4450

VL - 20

SP - 1096

EP - 1097

JO - Nature chemical biology

JF - Nature chemical biology

IS - 9

ER -

Another KRAS variant trapped

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this